Abstract
AIM
Sugar sweetened beverages (SSBs) are any beverages containing added-sugar and supposed to increase body lipogenesis and fat accumulation in healthy subjects. This study was performed to assess the possible association between SSBs consumption and obesity in type 2 diabetes (T2DM) patients.
METHODS
T2DM adults with no insulin treatment entered the study. Abdominal obesity and general adiposity were determined using waist circumference (WC) and body mass index (BMI), respectively. SSBs intake was extracted from a validated food frequency questionnaire.
RESULTS
Mean SSBs intake was 0.6 serving/d (145.6mL/d). There was no considerable association between SSBs intake and gender. About 46% of patients consumed at least one serving of SSBs per week. SSBs consumption was correlated neither to WC nor to BMI. After adjustment for confounding factors, abdominal obesity was associated with drinking SSBs ≥1 serving/week (OR=4.93, 95% CI: 1.35-18.03), and SSB ≥3 serving/week (OR=5.07, 95% CI: 1.22-21.15) compared to those consumed <1 serving/week. This association was not found for general obesity (OR=0.88, 95% CI: 0.60-1.23). Ex-smokers had higher SSBs intake compared to those never smoked (OR=3.94, 95% CI=1.06-14.71). Energy intake and macronutrients were similar in both SSBs sub-groups. Mean daily energy supplied by SSBs was 120kcal in participants having ≥1 serving of SSBs/week and 2.7kcal in <1 serving SSBs/week (OR=1.14, 95% CI: 1.09-1.20). Lower SSBs drinkers had 17% higher fiber intake (OR=0.83, 95% CI=0.73-0.96).
CONCLUSION
SSBs intake might increase abdominal obesity in diabetic population and therefore should be considered in diabetes control procedure.
TY - JOUR
T1 - Sugar-sweetened beverages consumption is associated with abdominal obesity risk in diabetic patients.
AU - Anari,Razieh,
AU - Amani,Reza,
AU - Veissi,Masoud,
Y1 - 2017/04/28/
PY - 2017/04/04/received
PY - 2017/04/27/accepted
PY - 2017/5/11/pubmed
PY - 2018/8/1/medline
PY - 2017/5/11/entrez
KW - Abdominal obesity
KW - Diabetes
KW - General obesity
KW - Smoking
KW - Sugar-sweetened beverages
SP - S675
EP - S678
JF - Diabetes & metabolic syndrome
JO - Diabetes Metab Syndr
VL - 11 Suppl 2
N2 - AIM: Sugar sweetened beverages (SSBs) are any beverages containing added-sugar and supposed to increase body lipogenesis and fat accumulation in healthy subjects. This study was performed to assess the possible association between SSBs consumption and obesity in type 2 diabetes (T2DM) patients. METHODS: T2DM adults with no insulin treatment entered the study. Abdominal obesity and general adiposity were determined using waist circumference (WC) and body mass index (BMI), respectively. SSBs intake was extracted from a validated food frequency questionnaire. RESULTS: Mean SSBs intake was 0.6 serving/d (145.6mL/d). There was no considerable association between SSBs intake and gender. About 46% of patients consumed at least one serving of SSBs per week. SSBs consumption was correlated neither to WC nor to BMI. After adjustment for confounding factors, abdominal obesity was associated with drinking SSBs ≥1 serving/week (OR=4.93, 95% CI: 1.35-18.03), and SSB ≥3 serving/week (OR=5.07, 95% CI: 1.22-21.15) compared to those consumed <1 serving/week. This association was not found for general obesity (OR=0.88, 95% CI: 0.60-1.23). Ex-smokers had higher SSBs intake compared to those never smoked (OR=3.94, 95% CI=1.06-14.71). Energy intake and macronutrients were similar in both SSBs sub-groups. Mean daily energy supplied by SSBs was 120kcal in participants having ≥1 serving of SSBs/week and 2.7kcal in <1 serving SSBs/week (OR=1.14, 95% CI: 1.09-1.20). Lower SSBs drinkers had 17% higher fiber intake (OR=0.83, 95% CI=0.73-0.96). CONCLUSION: SSBs intake might increase abdominal obesity in diabetic population and therefore should be considered in diabetes control procedure.
SN - 1878-0334
UR - https://www.unboundmedicine.com/medline/citation/28487104/Sugar_sweetened_beverages_consumption_is_associated_with_abdominal_obesity_risk_in_diabetic_patients_
L2 - https://linkinghub.elsevier.com/retrieve/pii/S1871-4021(17)30098-X
DB - PRIME
DP - Unbound Medicine
ER -
